Almirall S.A.

Research activity is centred on moderate-to-severe atopic dermatitis, with additional interest in nummular dermatitis and broader eczema management in adults and adolescents. The sponsor’s portfolio reflects sustained attention to disease control, symptom relief, and longer-term treatment use in chronic inflammatory skin disease.

  • Atopic dermatitis
  • Nummular dermatitis
  • Chronic inflammatory skin disease

These studies focus on persistent cutaneous inflammation and the clinical burden of recurrent pruritus, erythema, and skin barrier dysfunction.

Hidradenitis suppurativa and inflammatory skin disease

The sponsor is actively involved in research on moderate-to-severe hidradenitis suppurativa, covering both symptom burden and treatment tolerability in this difficult-to-manage inflammatory skin disorder. This area represents a major therapeutic focus within its dermatology pipeline.

  • Hidradenitis suppurativa
  • Inflammatory skin disease
  • Disease severity and tolerability

Work in this field addresses chronic nodular and suppurative lesions, with attention to patient populations experiencing ongoing disease activity and treatment need.

Actinic keratosis and cutaneous precancerous lesions

Another major area of interest is actinic keratosis, including lesions on the face and scalp. The sponsor’s studies in this field are directed toward lesion clearance and the management of sun-damaged skin with precancerous change.

  • Actinic keratosis
  • Face and scalp lesions
  • Cutaneous precancerous disease

This research area also includes attention to the risk of progression to squamous cell carcinoma in patients with actinic damage.

Alopecia areata and immune-mediated hair loss

The portfolio includes studies in alopecia areata, with a specific focus on adults affected by severe to very severe forms of autoimmune hair loss. This reflects interest in conditions driven by immune dysregulation affecting the hair follicle.

  • Alopecia areata
  • Autoimmune hair loss
  • Immune-mediated dermatology

These trials align with broader work in dermatologic diseases where immune pathways contribute to persistent visible symptoms and quality-of-life impact.

Beyond dermatology, the sponsor funds research in heartburn and reflux during pregnancy, with attention to maternal safety and foetal and newborn outcomes. This area extends its clinical interest into supportive care for common gastrointestinal symptoms in obstetric settings.

  • Heartburn and reflux
  • Pregnancy safety
  • Perinatal outcomes

The sponsor also shows interest in broader inflammatory diseases, indicating a therapeutic footprint that reaches beyond skin-focused indications.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study to evaluate the effectiveness and safety of LAD328 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Germany Poland Spain
  • A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

    Recruiting

    2 1
    Investigated diseases:
    Bulgaria Germany Poland Romania Spain
  • A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

    Recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Germany Italy Poland Spain
  • A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

    Recruiting

    2 1 1
    France Germany Ireland Italy Poland Spain
  • Safety Study of Almagate for Pregnant Women with Heartburn and Reflux, Assessing Effects on Mother and Baby

    Recruiting

    3 1 1 1
    Spain
  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Denmark France Italy Spain Sweden